NKT ligand-loaded, antigen-expressing B cells function as long-lasting antigen presenting cells in vivo

Cellular Immunology

Volumn 270, Issue 2, 2011, Pages 135-144

  Kim, Yeon Jeong ^a   Han, Seung Hee ^a   Kang, Ho Woong ^a   Lee, Jung Mi ^a   Kim, Yun Sun ^a   Seo, Jeong Hwan ^a   Seong, Yun Kyeong ^b   Ko, Hyun Jeong ^a,e   Choi, Tae Hyun ^c   Moon, Cheol ^d   Kang, Chang Yuil ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

^d Semyung University   (South Korea)

^e Kangwon National University   (South Korea)

Author keywords

Galactosylceramide; Adenovirus; B cell; Biodistribution; Cancer vaccine; Toxicity

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALPHA GALACTOSYLCERAMIDE; ASPARTATE AMINOTRANSFERASE; BETA CELL BASED VACCINE; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VACCINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VIVO STUDY; LIVER TOXICITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SPLEEN; TREATMENT DURATION;

ADENOVIRIDAE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CANCER VACCINES; GALACTOSYLCERAMIDES; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; LIGANDS; LIVER; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; NEOPLASMS; SPLEEN; TRANSFECTION;

ADENOVIRIDAE;

EID: 80051672797     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.04.006     Document Type: Article

References (41)

1. Schuster M., Nechansky A., Kircheis R. Cancer immunotherapy. Biotechnol. J. 2006, 1:138-147.
2. Goldman B. Cancer vaccines: finding the best way to train the immune system. J. Natl. Cancer Inst. 2002, 94:1523-1526.
3. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
4. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22:329-360.
5. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
6. Burgents J.E., Moran T.P., West M.L., Davis N.L., Johnston R.E., Serody J.S. The immunosuppressive tumor environment is the major impediment to successful therapeutic vaccination in Neu transgenic mice. J. Immunother. 2010, 33:482-491.
7. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
8. Chatten C., Bathe O.F. Immunoregulatory cells of the tumor microenvironment. Front Biosci. 2010, 15:291-308.
9. Morse M.A., Hall J.R., Plate J.M. Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin. Biol. Ther. 2009, 9:331-339.
10. Chung Y., Kim B.S., Kim Y.J., Ko H.J., Ko S.Y., Kim D.H., Kang C.Y. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res. 2006, 66:6843-6850.
11. Kim Y.J., Ko H.J., Kim Y.S., Kim D.H., Kang S., Kim J.M., Chung Y., Kang C.Y. Alpha-galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int. J. Cancer 2008, 122:2774-2783.
12. Ko H.J., Kim Y.J., Kim Y.S., Chang W.S., Ko S.Y., Chang S.Y., Sakaguchi S., Kang C.Y. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007, 67:7477-7486.
13. Henderson R.A., Mossman S., Nairn N., Cheever M.A. Cancer vaccines and immunotherapies: emerging perspectives. Vaccine 2005, 23:2359-2362.
14. Reilly R.T., Machiels J.P., Emens L.A., Ercolini A.M., Okoye F.I., Lei R.Y., Weintraub D., Jaffee E.M. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 2001, 61:880-883.
15. Zhou H., Luo Y., Kaplan C.D., Kruger J.A., Lee S.H., Xiang R., Reisfeld R.A. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Blood 2006, 107:3251-3257.
16. Fukushima S., Hirata S., Motomura Y., Fukuma D., Matsunaga Y., Ikuta Y., Ikeda T., Kageshita T., Ihn H., Nishimura Y., Senju S. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J. Immunother. 2009, 32:219-231.
17. Christ M., Louis B., Stoeckel F., Dieterle A., Grave L., Dreyer D., Kintz J., Ali Hadji D., Lusky M., Mehtali M. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum. Gene Ther. 2000, 11:415-427.
18. Teng M.W., Westwood J.A., Darcy P.K., Sharkey J., Tsuji M., Franck R.W., Porcelli S.A., Besra G.S., Takeda K., Yagita H., Kershaw M.H., Smyth M.J. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 2007, 67:7495-7504.
19. Biburger M., Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J. Immunol. 2005, 175:1540-1550.
20. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA 2000, 97:5498-5503.
21. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., Motoki K., Kamishohara M., Seki S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J. Immunol. 2001, 166:6578-6584.
22. Miyake S., Makimura M., Kanegae Y., Harada S., Sato Y., Takamori K., Tokuda C., Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. USA 1996, 93:1320-1324.
23. Penichet M.L., Challita P.M., Shin S.U., Sampogna S.L., Rosenblatt J.D., Morrison S.L. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 1999, 49:179-188.
24. Chang S.Y., Lee K.C., Ko S.Y., Ko H.J., Kang C.Y. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int. J. Cancer 2004, 111:86-95.
25. Toyabe S., Seki S., Iiai T., Takeda K., Shirai K., Watanabe H., Hiraide H., Uchiyama M., Abo T. Requirement of IL-4 and liver NK1+ T cells for concanavalin A - induced hepatic injury in mice. J. Immunol. 1997, 159:1537-1542.
26. Tiegs G., Hentschel J., Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 1992, 90:196-203.
27. Trowbridge I.S., Thomas M.L. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu. Rev. Immunol. 1994, 12:85-116.
28. Mullins D.W., Sheasley S.L., Ream R.M., Bullock T.N., Fu Y.X., Engelhard V.H. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 2003, 198:1023-1034.
29. Park M.Y., Kim H.S., Woo S.J., Kim C.H., Park J.S., Sohn H.J., Kim H.J., Oh S.T., Kim T.G. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells. Eur. J. Immunol. 2008, 38:2106-2117.
30. Tripp C.H., Sparber F., Hermans I.F., Romani N., Stoitzner P. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells. J. Immunol. 2009, 182:7644-7654.
31. Mehal W.Z., Juedes A.E., Crispe I.N. Selective retention of activated CD8+ T cells by the normal liver. J. Immunol. 1999, 163:3202-3210.
32. Giboney P.T. Mildly elevated liver transaminase levels in the asymptomatic patient. Am. Fam. Physician 2005, 71:1105-1110.
33. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
34. Li Z., Woo C.J., Iglesias-Ussel M.D., Ronai D., Scharff M.D. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev. 2004, 18:1-11.
35. Kodituwakku A.P., Jessup C., Zola H., Roberton D.M. Isolation of antigen-specific B cells. Immunol. Cell Biol. 2003, 81:163-170.
36. Delves P.J., Roitt I.M. The immune system. First of two parts. N. Engl. J. Med. 2000, 343:37-49.
37. Vieira P., Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 1988, 18:313-316.
38. Talbot P.J., Buchmeier M.J. Catabolism of homologous murine monoclonal hybridoma IgG antibodies in mice. Immunology 1987, 60:485-489.
39. Iyoda T., Ushida M., Kimura Y., Minamino K., Hayuka A., Yokohata S., Ehara H., Inaba K. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Int. Immunol. 2010, 22:905-913.
40. Chang W.S., Kim J.Y., Kim Y.J., Kim Y.S., Lee J.M., Azuma M., Yagita H., Kang C.Y. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 2008, 181:6707-6710.
41. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., Henderson J.M., Kutok J.L., Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008, 9:405-414.